Home › Companies › ENTA

Enanta Pharmaceuticals

Market cap $253M 29.2M shares (10-K, Nov 6, 2026) × $8.69 close Nov 17, 2026

Most recent annual filing: 2025-11-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. RESOLVE / LOTUS Ph2b readout2027RESOLVE / LOTUS Ph2b readout, 2027, notable
  2. EDP-978 Ph1 toplineFeb 2027EDP-978 Ph1 topline, Feb 2027, material
  3. STAT6 IND filing2Q 2027STAT6 IND filing, 2Q 2027, notable
  4. '265 Patent Pfizer opposition litigationApr 2027'265 Patent Pfizer opposition litigation, Apr 2027, routine
  5. MRGPRX2 IND filing4Q 2027MRGPRX2 IND filing, 4Q 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Capital (as filed)

Cash
$20.3M cash and cash equivalents · Sep 30, 2026 (10-K)
Short-term investments
$174M Sep 30, 2026
Operating cash flow
−$10.6M annual ÷ 4, year to Sep 30, 2026 (10-K)
As stated in coverage
$195M cash, runway fiscal 2029 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Enanta Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Enanta Pharmaceuticals (ENTA): Scientific Deep Dive for Lead and Pipeline Products Binary regulatory risk at the Q2 2026 FDA meeting on the RSV Phase 3 design warrants waiting before taking a position, with the cash/royalty floor providing a potential entry point on a negative outcome.
  2. Speculative buy speculative UPDATE: Enanta (ENTA) - Q1 2026 Financial Update Management's explicit RSV business development language de-risks the binary regulatory bet by signaling a potential partner could fund Phase 3, while smart money (Deep Track Capital) is stepping in alongside existing institutional holders.
  3. Speculative buy speculative UPDATE: Enanta (ENTA) - Q2 FY26 Sets the Clock on Zelicapavir The RSV partnership language survived the quarter intact alongside a hard-dated FDA path disclosure, the cash fortress is intact, and four meaningful catalysts in six months including two litigation lottery tickets maintain the asymmetric risk/reward.
  4. Buy core UPDATE: Enanta (ENTA) - The FDA Said Yes. The Market Said No. FDA acceptance of the HR3 subgroup Phase 3 design retires the single biggest abstract risk; the 18% drawdown into good news creates the entry the original BUY case described, with clinical risk now shifting to the more familiar 'will the effect replicate' form.
  5. Buy core UPDATE: Enanta (ENTA) - The Federal Circuit Tore Up One of the Lottery Tickets The U.S. patent loss was already priced in as a lottery ticket outcome, the EU acute-HCV label expansion provides a small royalty tailwind, and the core thesis of a wholly-owned antiviral in a $2.6-3.5B market backed by $227M cash remains intact.
  6. Watch UPDATE: Enanta (ENTA) - The Shelf Wasn't Just Housekeeping The $75M ATM activation signals no partner has materialized at acceptable terms and that Enanta is transitioning to self-funding Phase 3, introducing a 17.5% dilution overhang that dampens the asymmetry that made the stock compelling below $13.
  7. Speculative buy speculative UPDATE: Enanta (ENTA) - The ATM They Didn't Use Zero ATM issuance through June 30 and unchanged fiscal 2029 runway guidance confirm the shelf is defensive optionality rather than active financing, satisfying the key condition for reversing the July downgrade, though a 21% YoY royalty decline and five quarters of BD silence keep conviction at speculative rather than core.
  8. Speculative buy speculative UPDATE: Enanta (ENTA) - The Founder-Era CEO Steps Aside The planned CEO retirement is an orderly transition that doesn't change the science or cash runway, and the new COO's Vertex BD background may actually improve strategic optionality, but the bigger tests (ATM draw and EDP-978 data) haven't happened yet.
  9. Speculative buy speculative UPDATE: Enanta (ENTA) - The Last Lottery Ticket Comes Up Blank The UPC ruling invalidating the European Paxlovid patent removes the last non-dilutive upside path from litigation but doesn't change the core clinical thesis, which always rested on zelicapavir replicating and the oral biologics platform working in humans.
  10. Watch UPDATE: Enanta (ENTA) - The Catalysts Slip Into 2027 EDP-978 topline slipped to 1Q 2027, the STAT6 IND was delayed by a manufacturing problem, Farallon cut its stake from ~9-10% to 3.3%, and the royalty posted a second straight down quarter, leaving no catalysts scheduled for the rest of 2026 and turning this into a waiting story.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (7 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)